Deals
DuPont Considers Sale of Biosciences Unit That Could Fetch $20 Billion
- Company considers unloading nutrition and biosciences division
- Logical partners include International Flavors, DSM or Kerry
Photographer: Mark Makela/Getty Images
This article is for subscribers only.
The serial dealmaker running DuPont de Nemours Inc. is gearing up for another $20 billion-plus divestment that could become one of the chemical industry’s biggest transactions this year.
DuPont Chairman Ed Breen is considering unloading the company’s nutrition and biosciences business, one of its fastest-growing divisions, according to people familiar with the matter. A sale would extend a dramatic overhaul of DuPont’s portfolio as it looks to salvage shareholder value in the face of slowing markets and the U.S.-China trade war that has crimped growth.